Agenda

March 22-23, 2025

Available DatesRegister Now

March 22-23, 2025

September 13-14, 2025

Saturday March 22, 2025

8:00 AM – 9:00 AM

Non-CME Innovation Theater
9:00 AM – 9:05 AM

Movement Break
9:05 AM – 9:10 AM

Welcome
9:10 AM – 9:55 AM
Plenary 1: Diagnostic Biomarkers Testing/Liquid Biopsies
- Presenter
  - Andrew McKenzie
- Room:
  - Astor Ballroom
9:55 AM – 10:05 AM

Movement Break
10:05 AM – 10:35 AM
Session 1: Navigating the Evolving Treatment Landscape for EGFR-Mutated Non-Small Cell Lung Cancer
- Room:
  - Duffy/Columbia
10:05 AM – 10:35 AM
Session 1: Selected Topic in Gastrointestinal Cancers
- Room:
  - Astor Ballroom
10:05 AM – 10:35 AM
Session 1: Selected Topic in Women's Cancers
- Room:
  - Chelsea/Hudson
+

10:35 AM – 11:20 AM
Session 2: Debate: CTLA-4 Inhibition in Lung Cancer: The Time is Now or Never? Now vs Never
- Room:
  - Duffy/Columbia
- 10:35 AM – 10:55 AM
  CTLA-4 Inhibition in Lung Cancer: The Time is Now or Never? Now
- 10:55 AM – 11:15 AM
  CTLA-4 Inhibition in Lung Cancer: The Time is Now or Never? Never
+

10:35 AM – 11:20 AM
Session 2: Debate: Antibody Drug Conjugates: Should We Use Sequentially? Yes, They Are Better than Chemo vs No, the Benefit is Really Just for the First ADC
- Room:
  - Chelsea/Hudson
- 10:35 AM – 10:55 AM
  Antibody Drug Conjugates: Should We Use Sequentially? Yes, They Are Better than Chemo
- 10:55 AM – 11:15 AM
  Antibody Drug Conjugates: Should We Use Sequentially? No, the Benefit is Really Just for the First ADC
+

10:35 AM – 11:20 AM
Session 2: Debate: State-of-the-Art Management of Localized GEJ Cancer: Neoadjuvant vs. Adjuvant Therapy
- Moderator
  - Cathy EngMD, FACP, FASCO
  - Yelena JanjigianMD
- Room:
  - Astor Ballroom
- 10:35 AM – 10:55 AM
  State-of-the-Art Management of Localized GEJ Cancer: Neoadjuvant
- 10:55 AM – 11:15 AM
  State-of-the-Art Management of Localized GEJ Cancer: Adjuvant Therapy
11:20 AM – 12:05 PM

Exhibit Hall
12:05 PM – 12:35 PM
Session 3: Selected Topic in Lung Cancers
- Room:
  - Duffy/Columbia
12:05 PM – 12:35 PM
Session 3: Selected Topic in Gastrointestinal Cancers
- Room:
  - Astor Ballroom
12:05 PM – 12:35 PM
Session 3: Selected Topic in Women's Cancers
- Room:
  - Chelsea/Hudson
12:35 PM – 1:35 PM

Non-CME Innovation Theater
1:35 PM – 1:40 PM

Movement Break
+

1:40 PM – 2:25 PM
Session 4: Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer vs. In Combination with Chemotherapy in the First-Line Metastatic Setting
- Moderator
  - Kathleen MooreMD, MS
- Room:
  - Chelsea/Hudson
- 1:40 PM – 2:00 PM
  What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer
- 2:00 PM – 2:20 PM
  What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: In Combination with Chemotherapy in the First-Line Metastatic Setting
+

1:40 PM – 2:25 PM
Session 4: Debate in Gastrointestinal Cancers
- Moderator
  - Cathy EngMD, FACP, FASCO
  - Yelena JanjigianMD
- Room:
  - Astor Ballroom
- 1:40 PM – 2:00 PM
  Session 4: Debate in Gastrointestinal Cancers
- 2:00 PM – 2:20 PM
  Session 4: Debate in Gastrointestinal Cancers
+

1:40 PM – 2:25 PM
Session 4: Debate: PD-L1+ Lung Cancer: Monotherapy vs Combination with Chemotherapy
- Moderator
  - Corey LangerMD, FACP
  - Edward GaronMD, MS
- Room:
  - Duffy/Columbia
- 1:40 PM – 2:00 PM
  PD-L1+ Lung Cancer: Monotherapy
- 2:00 PM – 2:20 PM
  PD-L1+ Lung Cancer: Combination with Chemotherapy
2:25 PM – 2:55 PM
Session 5: Selected Topic in Lung Cancers
- Room:
  - Duffy/Columbia
2:25 PM – 2:55 PM
Session 5: Selected Topic in Gastrointestinal Cancers
- Room:
  - Astor Ballroom
2:25 PM – 2:55 PM
Session 5: Selected Topic in Women's Cancers
- Room:
  - Chelsea/Hudson
2:55 PM – 3:00 PM

Movement Break
3:00 PM – 4:00 PM

Non-CME Innovation Theater
4:00 PM – 5:00 PM
Session 6: Lung Cancers Roundtable
- Room:
  - Duffy/Columbia
4:00 PM – 5:00 PM
Session 6: Gastrointestinal Cancers Roundtable
- Room:
  - Astor Ballroom
4:00 PM – 5:00 PM
Session 6: Women's Cancers Roundtable
- Room:
  - Chelsea/Hudson
5:00 PM – 6:00 PM

Exhibit Hall Reception

Sunday March 23, 2025

8:00 AM – 9:00 AM

Non-CME Innovation Theater
9:00 AM – 9:05 AM

Movement Break
9:05 AM – 9:10 AM

Welcome
9:10 AM – 9:55 AM
Plenary 2: Tumor Agnostic Therapies - NTRK, KRAS, RET, MSI High, PDL1, HER2, TROP
- Invited Presenter
  - David Hong
- Room:
  - Astor Ballroom
9:55 AM – 10:05 AM

Movement Break
10:05 AM – 10:35 AM
Session 7: Selected Topic in Lung Cancers
- Room:
  - Duffy/Columbia
10:05 AM – 10:35 AM
Session 7: Selected Topic in Gastrointestinal Cancers
- Room:
  - Astor Ballroom
10:05 AM – 10:35 AM
Session 7: Selected Topic in Women's Cancers
- Room:
  - Chelsea/Hudson
+

10:35 AM – 11:20 AM
Session 8: Debate: Stage 3 Chemo-Radiation: Surgical vs Non-Surgical Approach
- Moderator
  - Corey LangerMD, FACP
  - Edward GaronMD, MS
- Room:
  - Duffy/Columbia
- 10:35 AM – 10:55 AM
  Stage 3 Chemo-Radiation: Surgical Approach
- 10:55 AM – 11:15 AM
  Stage 3 Chemo-Radiation: Non-Surgical Approach
+

10:35 AM – 11:20 AM
Session 8: Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease?: Platinum is the SOC vs It's Time to Move on From Platinum
- Moderator
  - Kathleen MooreMD, MS
- Room:
  - Chelsea/Hudson
- 10:35 AM – 10:55 AM
  For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease?: Platinum is the SOC
- 10:55 AM – 11:15 AM
  For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease?: It's Time to Move on From Platinum
+

10:35 AM – 11:20 AM
Session 8: Debate in Gastrointestinal Cancers
- Moderator
  - Cathy EngMD, FACP, FASCO
  - Yelena JanjigianMD
- Room:
  - Astor Ballroom
- 10:35 AM – 10:55 AM
  Session 8: Debate in Gastrointestinal Cancers
- 10:55 AM – 11:15 AM
  Session 8: Debate in Gastrointestinal Cancers
11:20 AM – 12:05 PM

Exhibit Hall
12:05 PM – 12:35 PM
Session 9: Selected Topic in Lung Cancers
- Room:
  - Duffy/Columbia
12:05 PM – 12:35 PM
Session 9: Selected Topic in Gastrointestinal Cancers
- Room:
  - Astor Ballroom
12:05 PM – 12:35 PM
Session 9: Selected Topic in Women's Cancers
- Room:
  - Chelsea/Hudson
12:35 PM – 1:35 PM

Non-CME Innovation Theater
1:35 PM – 1:40 PM

Movement Break
+

1:40 PM – 2:25 PM
Session 10: Debate: Front Line Targeted Therapies: Prioritize Efficacy or Minimize Toxicity?
- Moderator
  - Corey LangerMD, FACP
  - Edward GaronMD, MS
- Room:
  - Duffy/Columbia
- 1:40 PM – 2:00 PM
  Front Line Targeted Therapies: Prioritize Efficacy or Minimize Toxicity? Prioritize Efficacy
- 2:00 PM – 2:20 PM
  Front Line Targeted Therapies: Prioritize Efficacy or Minimize Toxicity? Minimize Toxicity
+

1:40 PM – 2:25 PM
Session 10: Debate: Optimal Frontline Therapy and Sequencing in Advanced HCC: VEGF Inhibition with ICI vs Dual Immune Checkpoint Blockade?
- Moderator
  - Cathy EngMD, FACP, FASCO
  - Yelena JanjigianMD
- Room:
  - Astor Ballroom
- 1:40 PM – 2:00 PM
  Optimal Frontline Therapy and Sequencing in Advanced HCC: VEGF Inhibition with ICI
- 2:00 PM – 2:20 PM
  Optimal Frontline Therapy and Sequencing in Advanced HCC: Dual Immune Checkpoint Blockade
+

1:40 PM – 2:25 PM
Session 10: Debate: Novel Endocrine Backbones: Should We Move Them into Earlier Lines of Therapy? Yes, They Will Make a Difference Here vs No, They Don't Add Much
- Moderator
  - Paolo TarantinoMD
- Room:
  - Chelsea/Hudson
- 1:40 PM – 2:00 PM
  Novel Endocrine Backbones: Should We Move Them into Earlier Lines of Therapy? Yes, They Will Make a Difference Here
- 2:00 PM – 2:20 PM
  Novel Endocrine Backbones: Should We Move Them into Earlier Lines of Therapy? No, They Don't Add Much
2:25 PM – 2:30 PM

Movement Break
2:30 PM – 3:30 PM

Non-CME Innovation Theater
3:30 PM – 4:30 PM
Session 11: Lung Cancers Roundtable
- Room:
  - Duffy/Columbia
3:30 PM – 4:30 PM
Session 11: Gastrointestinal Cancers Roundtable
- Room:
  - Astor Ballroom
3:30 PM – 4:30 PM
Session 11: Women's Cancers Roundtable
- Room:
  - Chelsea/Hudson

Available Dates

Agenda

March 22-23, 2025

Saturday March 22, 2025

Non-CME Innovation Theater

Movement Break

Welcome

Plenary 1: Diagnostic Biomarkers Testing/Liquid Biopsies

Movement Break

Session 1: Navigating the Evolving Treatment Landscape for EGFR-Mutated Non-Small Cell Lung Cancer

Session 1: Selected Topic in Gastrointestinal Cancers

Session 1: Selected Topic in Women's Cancers

Session 2: Debate: CTLA-4 Inhibition in Lung Cancer: The Time is Now or Never? Now vs Never

Session 2: Debate: Antibody Drug Conjugates: Should We Use Sequentially? Yes, They Are Better than Chemo vs No, the Benefit is Really Just for the First ADC

Session 2: Debate: State-of-the-Art Management of Localized GEJ Cancer: Neoadjuvant vs. Adjuvant Therapy

Exhibit Hall

Session 3: Selected Topic in Lung Cancers

Session 3: Selected Topic in Gastrointestinal Cancers

Session 3: Selected Topic in Women's Cancers

Non-CME Innovation Theater

Movement Break

Session 4: Debate: What is the Most Impactful Time to Use Immune Checkpoint Inhibitors: Locally Advanced Cervical Cancer vs. In Combination with Chemotherapy in the First-Line Metastatic Setting

Session 4: Debate in Gastrointestinal Cancers

Session 4: Debate: PD-L1+ Lung Cancer: Monotherapy vs Combination with Chemotherapy

Session 5: Selected Topic in Lung Cancers

Session 5: Selected Topic in Gastrointestinal Cancers

Session 5: Selected Topic in Women's Cancers

Movement Break

Non-CME Innovation Theater

Session 6: Lung Cancers Roundtable

Session 6: Gastrointestinal Cancers Roundtable

Session 6: Women's Cancers Roundtable

Exhibit Hall Reception

Sunday March 23, 2025

Non-CME Innovation Theater

Movement Break

Welcome

Plenary 2: Tumor Agnostic Therapies - NTRK, KRAS, RET, MSI High, PDL1, HER2, TROP

Movement Break

Session 7: Selected Topic in Lung Cancers

Session 7: Selected Topic in Gastrointestinal Cancers

Session 7: Selected Topic in Women's Cancers

Session 8: Debate: Stage 3 Chemo-Radiation: Surgical vs Non-Surgical Approach

Session 8: Debate: For Patients Who Have Progressed on (Or Following) PARPI Maintenance, What Is the Best Strategy for Treating Platinum-Sensitive Recurrent Disease?: Platinum is the SOC vs It's Time to Move on From Platinum

Session 8: Debate in Gastrointestinal Cancers

Exhibit Hall

Session 9: Selected Topic in Lung Cancers

Session 9: Selected Topic in Gastrointestinal Cancers

Session 9: Selected Topic in Women's Cancers

Non-CME Innovation Theater

Movement Break

Session 10: Debate: Front Line Targeted Therapies: Prioritize Efficacy or Minimize Toxicity?

Session 10: Debate: Optimal Frontline Therapy and Sequencing in Advanced HCC: VEGF Inhibition with ICI vs Dual Immune Checkpoint Blockade?

Session 10: Debate: Novel Endocrine Backbones: Should We Move Them into Earlier Lines of Therapy? Yes, They Will Make a Difference Here vs No, They Don't Add Much

Movement Break

Non-CME Innovation Theater

Session 11: Lung Cancers Roundtable

Session 11: Gastrointestinal Cancers Roundtable

Session 11: Women's Cancers Roundtable

Questions?